[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,47,79,105,130,153,178,215,238,269,292,334,361,380,398,421,449,477,499,523,549,578,605,628,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100601411","tongue-proactive-strengthening-exercise-program-following-partialhemi-glossectomy-and-reconstruction-100601411",false,"NCT07110142","Tongue Proactive Strengthening Exercise Program Following Partial\u002FHemi Glossectomy and Reconstruction","Impact of Tongue Proactive Strengthening Exercise Program on Speech and Swallowing Outcomes Following Partial\u002FHemiglossectomy and Reconstruction","T-PROSE","Inclusion Criteria:\n\n1. ≥18 years of age\n2. No prior history of head and neck cancer\n3. No prior history of radiation\n4. Planned to undergo resection of ≤50% of the native tongue (partial\u002Fhemiglossectomy) with immediate reconstruction, including free flap reconstruction, and with or without neck dissection\n5. Sufficiently fluent in written English, French, Spanish or Simplified Chinese to complete the study outcomes questionnaires\n\nExclusion Criteria:\n\n1. Distant metastasis at enrollment\n2. Previously seen and treated by speech and language pathologist for dysphagia or dysarthria for non-head and neck cancer causes\n3. Prior head and neck radiation\n4. Requires mandibulectomy or \\>50% resection of native tongue","ALL","18 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is being done to determine whether adding a proactive tongue strengthening exercise program using a biofeedback device (the Tongueometer) improves speech and swallowing outcomes after surgery for tongue cancer. Patients who undergo partial or hemiglossectomy often experience difficulties with speech and swallowing, which can significantly impact their quality of life. While speech and swallow therapy is typically provided in response to problems, this study investigates whether introducing structured tongue strengthening exercises with biofeedback early-can lead to better long-term outcomes. This research will help establish whether this approach should become part of standard post-operative care.",[28,29],"Oral Cancer","Head and Neck Cancer",[31,32,33],"Speech-Language Pathology","Hemiglossectomy","Tongueometer","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-12-10",{"date":42,"type":22},"2029-06",{"name":44,"class":45},"Case Comprehensive Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100643729","a-feasibility-study-of-ai-assisted-physiotherapy-for-oral-cancer-patients-100643729","NCT07635381","A Feasibility Study of AI-Assisted Physiotherapy for Oral Cancer Patients","A Feasibility Study of AI-Assisted Physiotherapy for Oromandibular and Neck-Shoulder Mobility in Oral Cancer Patients","Inclusion Criteria:\n\n* Oral cancer patients with trismus, clinical signs of neck or shoulder joint impairment after oral cancer surgery or radiotherapy in recent 12 months\n* Age between 20 and 70 years\n\nExclusion Criteria:\n\n* Could not communicate\n* Had any disorder that could influence movement performance (e.g., stroke, Parkinsonism, head injury)","20 Years","70 Years",{"count":57,"type":22},15,[25],"This study aims to evaluate the feasibility, safety, and acceptability of a newly developed artificial intelligence (AI)-assisted physiotherapy system for oromandibular and neck-shoulder range of motion (ROM) in patients who have undergone treatment for oral cancer.\n\nIn this single-group, prospective, non-randomized pilot study, recruited participants will receive 4 to 6 weeks of AI-assisted physiotherapy. Participants will undergo a comprehensive clinical evaluation at baseline and post-intervention. During the intervention period, the AI system will perform a daily automated assessment to dynamically generate and adjust personalized exercise programs. Participants will perform these prescribed programs 4 to 6 times daily. Pre- and post-intervention changes, along with key feasibility parameters, acceptability, and safety metrics, will be statistically analyzed to inform future definitive trials.",[61,28],"AI (Artificial Intelligence)",[63,64,65,66,67,68],"Oral cancer","Artificial intelligence","Maximum interincisal opening","Physiotherapy","Range of motion","Neck and shoulder","NOT_YET_RECRUITING","2026-06-08",{"date":72,"type":38},"2026-06-09",{"date":74,"type":22},"2026-06-15",{"date":76,"type":22},"2027-12-31",{"name":78,"class":45},"National Taiwan University Hospital",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100564291","phase-2-antibiotic-treatment-effects-on-intratumoral-bacteria-modulation-in-surgical-patients-with-oral-cancer-100564291","NCT06627270","Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer","A Phase II Single-arm Cohort Study Establishing the Effect of Antibiotic Treatment on Intratumoral Bacteria in Surgical Patients With Oral Cancer","Inclusion Criteria:\n\n* Pathologically confirmed squamous cell carcinoma of the oral cavity\n* Must have planned surgery for curative intent\n* Participants ≥ 18 years of age\n* Participants must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Known allergy to metronidazole and\u002For chlorhexidine\n* Severe liver or kidney disease as determined by history of laboratory tests\n* Participants actively drinking alcohol (unable to abstain for the 10 day antibiotic period)\n* Recurrent oral cancer after prior radiation or chemoradiation\n* Participants with unresectable oral cancer\n* Participants unable to tolerate oral rinse or unable to have metronidazole administered by mouth or by feeding tube\n* Participants currently or have taken other antibiotics within the prior 30 days\n* Participant is pregnant",{"count":87,"type":22},30,[89],"PHASE2","The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.",[92,28,29,93],"Oral Squamous Cell Carcinoma","Head and Neck Carcinoma",[95,96],"Metronidazole","Chlorhexidine","2026-06-03",{"date":99,"type":38},"2026-06-04",{"date":101,"type":38},"2025-03-11",{"date":103,"type":22},"2027-10-01",{"name":44,"class":45},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":46},"100472224","mandibular-reconstruction-preplanning-vipmr-100472224","NCT05429099","Mandibular Reconstruction Preplanning (ViPMR)","Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial","ViPMR","Inclusion Criteria:\n\n* primary diagnosis requiring mandibulectomy and fibular or scapular free flap reconstructive surgery\n* are over the age of 18\n* cognitive ability and language skills that allow participation in the trial\n* provide informed consent\n\nExclusion Criteria:\n\n* severe comorbidities including metastatic disease\n* do not have a recent (within 30 days) CT scan and are unable\u002Funwilling to receive a head CT scan at the latest 6 days prior to surgery\n* prior history of head or neck cancer within last 5 years\n* prior history of head or neck radiation treatment at any time\n* pregnant of lactating women",{"count":114,"type":22},420,[25],"Virtual Surgical Planning (VSP), where 3D modeling is used to create 3D-printed surgical guides, has been shown to improve outcomes for patients who undergo mandibular reconstruction surgery, usually due to invasion of cancer from the oral cavity to the jaw. This trial will directly compare the outcomes of patients who receive VSP versus patients who receive the current standard of care, which is Free-Hand Surgery (FHS). They will be randomized into either treatment at a 1:1 ratio and bony union rates will be compared between 12-month postoperative CT scans for each treatment group. Secondary objectives include comparing other short and long-term complication rates, reconstruction accuracy, quality of life, and functional outcomes of VSP and FHS. An economic analysis of VSP will also be performed.",[118,28],"Oral Cavity Cancer",[118,28,120],"Mandibular Reconstruction","2026-05-28",{"date":123,"type":38},"2026-06-01",{"date":125,"type":38},"2022-10-15",{"date":127,"type":22},"2028-10-15",{"name":129,"class":45},"University of British Columbia",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100568492","defining-mechanisms-of-surgical-site-infection-after-oral-cancer-surgery-100568492","NCT06681935","Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery","Inclusion Criteria:\n\n1. Provide signed and dated informed consent form. Subjects must have the capacity to consent for themselves.\n2. Willing to comply with all study procedures and be available for the duration of the study.\n3. Aged 21 years or older.\n4. Planned to undergo standard of care oral cavity reconstruction surgery with use of ampicillin\u002Fsulbactam as the prophylactic antibiotic agent administered.\n5. Oral cavity reconstruction surgery will be defined as any surgical procedure which includes a planned connection from the oral cavity to the neck soft tissues which is repaired with a free or regional tissue flap.\n6. History of oral or oropharyngeal cancer.\n\nExclusion Criteria:\n\n1. Allergy to ampicillin\u002Fsulbactam.\n2. Vulnerable populations including pregnant women and prisoners.","21 Years",{"count":21,"type":22},"OBSERVATIONAL","The study design is an observational cohort study of patients undergoing standard of care oral cavity reconstruction. An observational study is required to prospectively evaluate microbial and antibiotic mechanisms underlying surgical site infection after oral cavity reconstruction.",[28],[142,143],"Surgical Site Infection","Oral Cavity Reconstruction","2026-05-19",{"date":146,"type":38},"2026-05-22",{"date":148,"type":38},"2025-04-29",{"date":150,"type":22},"2026-07-15",{"name":152,"class":45},"Medical College of Wisconsin",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":160,"enrollmentInfo":161,"targetDuration":163,"studyType":138,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100588463","relationship-between-mouth-opening-and-masseter-elasticity-in-oral-cancer-100588463","NCT06941727","Relationship Between Mouth Opening and Masseter Elasticity in Oral Cancer","Association Between Maximum Mouth Opening and Masseter Muscle Elasticity in Oral Cancer Patients: A Study Using Sonographic Elastography","Inclusion Criteria:\n\n1. Newly diagnosed oral cancer patients who are scheduled to receive cancer-related treatments (e.g., oral cancer surgery, radiotherapy, chemotherapy, or chemoradiotherapy).\n2. Age between 20 and 65 years.\n\nExclusion Criteria:\n\n1. Could not communicate.\n2. Had any disorder that could influence movement performance.","65 Years",{"count":162,"type":22},10,"8 Weeks","The study aims to assess the hardness of masticatory muscles in post-surgical oral cancer patients using strain elastography ultrasound, calculating the masseter elasticity index and exploring its association with maximum interincisal mouth opening. Furthermore, the study incorporates exercise training to analyze whether changes in masseter hardness can serve as an objective indicator for predicting the improvement of trismus.",[28],[65,167,168,169],"Elastography","Masseter muscle","Elasticity","2026-05-14",{"date":172,"type":38},"2026-05-18",{"date":174,"type":38},"2025-05-16",{"date":176,"type":22},"2026-12-31",{"name":78,"class":45},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100567833","phase-1-brodalumab-in-the-treatment-of-immune-related-adverse-events-100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":186,"type":22},11,[188],"PHASE1","The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[191,192,193,194,195,196,197,198,199,200,201,29,28,202,203,204,205,206],"Breast Cancer","Esophageal Cancer","Kidney Cancer","Lung Cancer","Thyroid Cancer","Gynecologic Cancer","Pancreatic Cancer","Stomach Cancer","Brain Tumor","Colon Cancer","Rectal Cancer","Liver Cancer","Skin Cancer","Prostate Cancer","Testicular Cancer","Solid Tumor","2026-05-11",{"date":209,"type":38},"2026-05-13",{"date":101,"type":38},{"date":212,"type":22},"2027-11",{"name":214,"class":45},"Brian Henick, MD",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100608619","surgeon-performed-ultrasound-for-real-time-guidance-in-oral-cancer-surgeries---a-multicenter-randomized-controlled-trial-100608619","NCT07203911","Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial","SURGIO","Inclusion criteria\n\n• Patients scheduled for surgical treatment of biopsy-proven T1-T3 oral squamous cell carcinoma.\n\nExclusion criteria\n\n* Age \\\u003C 18 years.\n* Oral cancer with suspected bone involvement.\n* Unable to understand verbal or written information.\n* Prior radiotherapy treatment of oral cavity cancer.\n* Tumor not visible on ultrasound.",{"count":223,"type":22},150,[25],"The goal of this clinical trial is to improve the surgical treatment of patients with oral cancer. We will explore whether the use of surgeon performed ultrasound during these surgeries result in better tumor removal. We hypothesize that using intraoperative ultrasound to assist the resection results in more frequent clear surgical margins in oral cancer surgeries compared to standard methods. This improvement is associated with a reduced need for post-operative adjuvant therapies such as radiotherapy and reoperation, lower mortality rates, lower cancer recurrence, and enhanced quality of life for patients undergoing surgery for oral cancer.\n\nParticipants will be randomized to either the control or intervention group:\n\n* Control group will receive standard treatment for oral cancer.\n* Intervention group will in addition to the standard treatment have surgery performed using ultrasound to guide the resection and evaluate resection margins intraoperatively.\n\nOutcomes:\n\n* Number of free surgical margins between control and intervention group.\n* Intraoperative surgeon assessed surgical margins compared to final histology report.\n* Dysphagia and quality of life questionnaires.\n* Recurrence rates.\n* Mortality rates.\n\nAll participant will be followed-up at 3 months and 12 months with:\n\n* MDADI dysphagia questionnaire\n* EORTC head and neck cancer quality of life questionnaire\n* Follow-up on recurrrence and mortality.",[227,28,228],"Tongue Cancer","Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","2026-05-10",{"date":209,"type":38},{"date":232,"type":38},"2025-09-15",{"date":234,"type":22},"2031-08",{"name":236,"class":45},"Tobias Todsen",7,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":256,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":46},"100568535","enhancing-oral-cancer-awareness-100568535","NCT06682494","Enhancing Oral Cancer Awareness","Comparative Study on Enhancing Oral Cancer Awareness: Classical Educational Materials vs. AI-Powered Chatbot","Inclusion Criteria:\n\n* Identify as African American as defined by the US Census\n* Participants must be able to read, speak, and write in English\n\nExclusion Criteria:\n\n* Individuals who cannot physically or mentally participate in the research project will be excluded\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners",true,{"count":247,"type":22},60,[25],"To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention",[28,251,252,253,254,255],"Chatbot","Patient Education","Prevention","Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer","Oropharyngeal Cancers",[257,258,259],"AI-powered Chatbox","Oral cancer prevention","Socio-economic barriers","2026-05-07",{"date":262,"type":38},"2026-05-08",{"date":264,"type":38},"2025-09-24",{"date":266,"type":22},"2027-10-31",{"name":268,"class":45},"Virginia Commonwealth University",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":46},"100253924","prosthesis-guided-speech-rehabilitation-of-t1t2-cancers-of-the-tongue-100253924","NCT02584270","Prosthesis Guided Speech Rehabilitation of T1\u002FT2 Cancers of the Tongue","Prosthesis Guided Speech Rehabilitation of T1\u002FT2 Cancers of the Tongue (PGSRT): a Randomized Clinical Trial","PGSRT","Inclusion Criteria:\n\n* Patients with a new diagnosis of a T1\u002FT2 tongue cancer\n\nExclusion Criteria:\n\n* Patients with recurrent disease\n* Patients with a history of prior head and neck radiation therapy\n* Patients who lack adequate maxillary dentition to support a palatal augmentation prosthesis",{"count":21,"type":22},[25],"This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery. This is a robust scientific randomized prospective clinical trial.\n\nPositive outcomes from this study have the potential to dramatically alter the most common issues of oral cancer therapy, namely speech and swallowing functions. Patients will have been diagnosed with a cancer lesion of the tongue requiring surgery and removal of part of the tongue. Smaller cancers of the tongue are sized as T1 or T2. For patients with smaller lesions, a PAP, which can aid in speaking and swallowing, is not routinely provided.",[281,227,28],"Tongue Neoplasms",[283],"palatal drop prosthesis","2026-05-05",{"date":262,"type":38},{"date":287,"type":38},"2018-01-02",{"date":289,"type":22},"2028-06",{"name":291,"class":45},"University of Michigan",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":245,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":315,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":333},"100636162","develop-and-evaluate-an-artificial-intelligence-assisted-prehabilitation-program-for-returning-to-work-and-cost-effectiveness-analysis-in-patients-with-oral-cancer-100636162","NCT07562100","Develop and Evaluate An Artificial Intelligence Assisted Prehabilitation Program for Returning to Work and Cost-effectiveness Analysis in Patients With Oral Cancer","Inclusion Criteria:\n\n* Adult (\\> 20 years old and younger than 70 years old)\n* Newly diagnosed as OC and scheduled to receive cancer-related treatment\n* Able to use Mobile phone\n* Willing to sign an informed consent form after receiving a detailed explanation of the study's aims and procedures\n* Healthcare professionals involved in patients' care, including doctors, nurses, case managers, dietitians, rehabilitation therapists, and psychologists\n* Family members who are primary caregivers of the participating patients, engaged in different stages of medical care\n\nExclusion Criteria:\n\n* Risk populations for walking or performing exercise\n* Patients with cognitive impairment or psychiatric diseases",{"count":299,"type":22},650,[25],"The goal of this clinical trial is to develop and evaluate an Artificial Intelligence Assisted Prehabilitation Program (AI APP) for returning to work and cost-effectiveness analysis in patients with oral cancer (OC). The main questions it aims to answer are:\n\n* What kinds of needs are related to returning to work (RTW) in patients with OC from diagnosis to survival that we can incorporate into the development of AI APP to assist this population ?\n* How is the effect of the AI APP that based on findings from the first question for patients with OC on physical and psychological distress, fear of recurrence, self-efficacy in coping with cancer, communication, motor function, quality of life, and RTW?\n* How is the effect of the RTW AI prediction model to identify high-risk groups ? And how is the comprehensive cost effectiveness of benefits and quality of life of the AI APP for OC population?\n\nResearchers will compare patients without using AI APP to see if the AI APP works to assist with coping physical and psychological distress, communication, motor function, quality of life, and RTW issues for individuals with OC?\n\nParticipants will:\n\n* Be asked to fulfill a structural questionnaire, or engage in a semi-structured one-by-one interview or a focus group to assess their physical, psychological, and social support needs in the first stage.\n* Be invited to participant the pilot testing of AI APP in the second stage.\n* Be provided and trained by 3-month AI APP for 3 months or cared as usual in the third stage.\n* Complete a structural questionnaire and follow up one year, including the baseline (before using the AI app) and at 1-2 weeks, 3 months, 6 months, 9 months, and 12 months after the baseline.\n* Engage in one-by-one interview or a focus group to assess user experiences of the AI APP.",[28,303,304,66,305,306,307,308,309,310,311,312,313,314],"Psychological Distress","Communication Aids for Disabled","Return to Work","Prehabilitation","Physical Symptom Distress","Motor Function","Rehabilitation","Quality of Life","Cost Effectiveness","Artifical Intelligence","Prediction Model","Case Management, APP(Application)",[316,305,28,303,304,66,306,317,318,309,319,320,321,322],"Artificial Intelligence","Physical symptom distress","motor function","Quality of life","Cost effectiveness","prediction model","case management, APP(Application)","2026-04-24",{"date":325,"type":38},"2026-05-01",{"date":327,"type":38},"2024-09-27",{"date":329,"type":22},"2029-12-01",{"name":331,"class":332},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",5,{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":349,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":46},"100612958","evaluation-of-two-non-invasive-methods-high-resolution-microendoscopy-and-liquid-based-cytology-for-detection-of-oral-precancer-100612958","NCT07260344","Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral Precancer","Inclusion Criteria:\n\n* Individuals aged 30-80 years\n* Individuals with visible oral precancerous lesions of at 1 cm in greatest diameter\n\nExclusion Criteria:\n\n* Individuals who are undergoing current cancer treatment or had a cancer within the last 12 months\n* Individuals who are unwilling or unable to provide informed consent to participate","30 Years","80 Years",{"count":343,"type":22},400,[25],"Cancers of the oral cavity (lip, oral tongue, gingivae, floor of mouth, hard palate, and other mouth tissues including buccal mucosa) are amongst the most common worldwide, with an estimated annual burden of over 300,000 incident cases. Most oral cancers (\\>75%) are attributable to cigarette smoking, alcohol drinking, and chewing of areca nut\u002Fbetel quid with or without tobacco, and very few are related to human papillomavirus infection. Oral cancer incidence geographically tracks with the prevalence of these risk factors and is notably high in the Indian subcontinent (due to tobacco chewing and smoking) and southeast Asia (due to betel quid chewing without tobacco and smoking).\n\nThe current standard for screening for oral precancer\u002Fcancer is visual and tactile examination by an expert for the presence of clinical\u002Fvisual lesions (leukoplakia, erythroplakia, and oral submucous fibrosis). Such visually identified lesions are further triaged based on clinical impression for a biopsy to determine histopathologic presence\u002Fgrade of dysplasia. Several observations point to key limitations of oral cancer screening based on clinical impression-based biopsy of visually identified lesions, including the decision to biopsy a lesion, which lesion to biopsy, and where within the lesion to direct a biopsy. Thus, there is a need for tools for improved triage of visual precancers for biopsy and targeting areas for biopsy within a lesion for more effective risk stratification and better provision of care.\n\nTwo non-invasive methods hold promise for triage of lesions for biopsy-oral liquid-based cytology and high-resolution microendoscopy (HRME). Oral cytology provides a method to non-invasively sample visible oral lesions and holds promise to enable triage of lesions for biopsy. HRME utilizes optical fiber-based imaging in combination with the fluorescent contrast agent proflavine to image sub-cellular features in vivo in lesions\u002Fepithelial tissues, functionally an in situ biopsy.\n\nThe investigators propose to conduct a cross-sectional study to evaluate the clinical utility of these two non-invasive methods for detecting oral precancer and early oral cavity cancer- the performance of oral cytology and HRME as an adjunct for triage of visible lesions for biopsy and the performance of HRME as an adjunct to enable better within-lesion targeting of areas for biopsy. If successful, this study would facilitate the development of a non-invasive, 3-step algorithm for oral cancer screening: identification of lesions through visual inspection, triage for biopsy through cytology or HRME, and targeted within-lesion biopsy (if needed) through HRME.",[347,28,348],"Oral Precancer","Oral Cancer Screening",[350],"oral cancer screening","2026-04-13",{"date":353,"type":38},"2026-04-14",{"date":355,"type":38},"2025-12-15",{"date":357,"type":22},"2029-01-30",{"name":359,"class":360},"Anil Chaturvedi","NIH",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":46},"100558356","clinical-and-molecular-features-of-oral-premalignancy-and-oral-cancer-100558356","NCT06550050","Clinical and Molecular Features of Oral Premalignancy and Oral Cancer","Clinical and Molecular Features of Oral Premalignancy and Oral Cancer Associated With Tumor Initiation, Aggressive Behavior, Treatment Response, and Survival Outcomes","* Aged 18 or older, with a diagnosis of oral premalignant or malignant tumors (eligible diagnoses listed below) or presenting with suspected premalignant or malignant tumors for definitive diagnosis\n* Must be able to provide informed consent\n* Oral premalignant or malignant tumors presenting for evaluation for the first time at UT MD Anderson Cancer Center\n* Oral premalignant or malignant tumors who were previously treated or evaluated at UT MD Anderson Cancer Center who presents for evaluation of progressive or recurrent disease. Newly collected biospecimens and tissue samples will be linked to applicable samples previously collected and banked\u002Fstored under PA17-0050, LAB02-427, Lab02-039 and Lab08-0848.\n\nEligible diagnoses include:\n\n* Leukoplakia\n* Erythroplakia\n* Mild dysplasia\n* Moderate dysplasia\n* Severe dysplasia\n* Carcinoma in situ\n* Squamous cell carcinoma\n\nExclusion:\n\n\\- Pregnant women and\u002For cognitively-impaired adults are excluded from this study.\n\nExclusion Criteria:\n\n\\- Prior oral squamous cell carcinoma (OSCC) surgery or OSCC radiation treatment at a non-MDA institution.",{"count":369,"type":22},1000,"Investigators will employ serial assessments of tissue biopsy and additional biomarkers that reflect burden of disease and predict treatment response. Patients enrolled on this study will be given the option to provide biological samples before, during, and after treatment, as well as functional outcomes of treatment response. These samples will be utilized to develop and validate prognostic and predictive biomarkers for patients undergoing targeted therapy, immunotherapy, surgery, chemotherapy, and\u002For radiotherapy.",[28],{"date":373,"type":38},"2026-04-16",{"date":375,"type":38},"2024-10-31",{"date":377,"type":22},"2066-12-31",{"name":379,"class":45},"M.D. Anderson Cancer Center",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":245,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":387,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":46},"100632125","ai-based-physiotherapy-evaluation-system-for-range-of-motion-in-oral-cancer-patients-100632125","NCT07509619","AI-based Physiotherapy Evaluation System for Range of Motion in Oral Cancer Patients","Validity and Reliability of an AI-based Physiotherapy Evaluation System for Oromandibular and Neck-Shoulder Range of Motion in Oral Cancer Patients","Inclusion Criteria:\n\n* Healthy adults aged 20 to 70 years\n* No trismus\n* No history of head, neck, or shoulder injury or surgery\n* No history of head and neck cancer-related radiotherapy or chemotherapy\n\nExclusion Criteria:\n\n* Inability to communicate or follow instructions\n* Any condition that may affect movement performance",{"count":388,"type":22},20,"This study aims to evaluate the validity and reliability of a novel AI-based physiotherapy evaluation system for measuring oromandibular and neck-shoulder range of motion (ROM). Traditional ROM assessments rely on manual measurements, which may be influenced by rater experience and variability. The proposed AI system uses automated keypoint tracking to provide objective and standardized measurements.\n\nIn this cross-sectional study, healthy adult participants will perform standardized ROM tasks. Measurements obtained from the AI system will be compared with those from two independent raters using conventional clinical tools. Repeated measurements will be conducted to assess intra-rater and inter-rater reliability. The agreement between the AI system and human raters will be evaluated to determine the system's clinical applicability.",[28,61],[63,64,65,66,67,68],"2026-04-06",{"date":351,"type":38},{"date":395,"type":38},"2026-04-07",{"date":76,"type":22},{"name":78,"class":45},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":160,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":420},"100576419","ai-based-physiotherapy-for-oral-cancer-patients-100576419","NCT06785051","AI-based Physiotherapy for Oral Cancer Patients","Effects of AI-Based Physiotherapy on Mandibular Mobility, Shoulder Function, Whole-Body Physical Function, and Quality of Life in Oral Cancer Patients","Inclusion Criteria:\n\n* Newly diagnosed oral cancer patients who are scheduled to receive cancer-related treatments (e.g., oral cancer surgery, radiotherapy, chemotherapy, or chemoradiotherapy).\n* Age between 20 and 65 years.\n\nExclusion Criteria:\n\n* Could not communicate.\n* Had any disorder that could influence movement performance.",{"count":406,"type":22},100,[25],"This study examines the effects of AI-based physiotherapy on oral function, shoulder function, whole-body physical function, and quality of life in oral cancer patients. One hundred patients will be recruited before surgery, chemotherapy, or radiotherapy and randomly assigned to an experimental group receiving 12 weeks of AI-guided physiotherapy or a control group receiving usual care. Both groups will perform jaw, neck, and shoulder exercises, with the experimental group using a mobile app to monitor progress. Assessments at baseline, pre-intervention, and 3 months post-intervention will measure maximal in the maximum interincisal opening (MIO), joint range of motion (ROM), pain, endurance (e.g., 6-minute walk test), upper extremity function, and quality of life.",[28],[64,63,65,411,306,66],"Physical function","2026-03-30",{"date":414,"type":38},"2026-04-03",{"date":416,"type":38},"2025-02-19",{"date":418,"type":22},"2027-07-31",{"name":78,"class":45},2,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":436,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":46},"100628835","resection-and-defect-repair-of-oral-cancer-aided-by-mixed-reality-technology-100628835","NCT07466810","Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology","Prospective Clinical Study in Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology Based on UE5 Engine","Inclusion Criteria:\n\n1. Definite pathological diagnosis of oral cancer before surgery;\n2. Defects suitable for free flap reconstruction;\n3. Patients have signed the informed consent form and are willing to cooperate with postoperative follow-up.\n\nExclusion Criteria:\n\n\\- Poor general condition, evaluated as unable to tolerate surgical treatment.\n\n-Exclusion Criteria (After Enrollment)\n\nSubjects who have been enrolled in this trial will be excluded if they meet any of the following conditions:\n\n1. Violation of important inclusion criteria;\n2. Subjects did not receive surgical treatment;\n3. No observation data after randomization. Withdrawal Criteria Withdrawal of subjects from the trial refers to cases where enrolled subjects are determined by the investigator to withdraw from the trial due to conditions that make it inappropriate to continue the trial. In accordance with the informed consent form, subjects have the right to withdraw from the trial midway. Subjects who do not explicitly propose to withdraw but stop receiving treatment and tests and are lost to follow-up are also considered \"withdrawn\" (or \"lost to follow-up\"). The reason for withdrawal should be understood and recorded as much as possible, such as: poor subjective curative effect; inability to tolerate certain adverse reactions; inability to continue participating in the clinical study due to personal reasons; economic factors; or lost to follow-up without stating the reason.\n\n(1) Aggravation or deterioration of the condition during the trial that requires emergency measures; (2) Occurrence of certain comorbidities, complications or special physiological changes in subjects during the trial, making it inappropriate to continue participating in the trial; (3) Voluntary withdrawal by the subject.\n\nData Handling of Withdrawn Subjects\n\nRegardless of the reason, the complete clinical data of subjects who withdraw from the trial shall be retained. For all withdrawn subjects, the trial conclusion form and the reason for withdrawal shall be filled in the case report form (CRF). Generally, there are 6 types of reasons: occurrence of adverse events (including adverse drug reactions and allergic reactions), lack of efficacy (deterioration of condition or occurrence of complications), violation of the trial protocol (including poor compliance), lost to follow-up (including voluntary withdrawal by the patient), termination by the sponsor, or others.",{"count":87,"type":22},[25],"The objective of this exploratory clinical trial is to apply Unreal Engine 5 (UE5)-based Mixed Reality (MR) technology to achieve real-time stereoscopic visualization of surgical planning, personalized free flap harvest and defect reconstruction, accurate oral cancer resection, and precise morphological and volumetric matching of the reconstructed free flap to the defect site.\n\nResearchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality \\[MR\\] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group.\n\nThe primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.",[432,433,434,435,28],"Tongue Squamous Cell Carcinoma","Mixed Reality","Virtual Surgical Planning","Free Flap",[433,437,438,439,440,435,434,28],"tongue reconstruction","Unreal Engine 5","Glossectomy","Surgical guide","2026-03-18",{"date":443,"type":38},"2026-03-20",{"date":445,"type":22},"2026-04-01",{"date":103,"type":22},{"name":448,"class":45},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":160,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":420},"100583416","phase-2-low-cost-screening-and-image-guided-photodynamic-therapy-pdt-of-premalignant-and-malignant-oral-lesions-100583416","NCT06876038","Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions","A Comprehensive Platform for Low-cost Screening and Image-guided Photodynamic Therapy (PDT) Treatment of Pre-malignant and Malignant Oral Lesions in Low-resource Setting","Subject Inclusion Criteria\n\n1. One grossly visible OPML, with histopathologically confirmed diagnosis of moderate, severe, and carcinoma in situ measuring ≥ 10 mm in diameter.\n2. Willing and available for follow-up for at least one year and at prerequisite time intervals.\n3. All patients above the age of 18 years and willing to voluntarily give a signed informed consent.\n4. Karnofsky Performance Score above 80 or ECOG 0 or 1.\n5. The subjects meeting the following laboratory eligibility criteria during a time not older than 2 months before accrual\n\n   * Hemoglobin level above or equal to 10%\n   * WBC \\>3000\u002Fmm3\n   * Platelets count \\>100000\u002Fmm3\n   * Total bilirubin, AST (SGOT), ALT (SGPT) \\\u003C 1.5 times the Upper Limit Normal\n   * eGFR \\> 60 ml\u002Fmin\n   * Serum Creatine less than 2 times the Upper Limit of laboratory normal\n   * INR\u002F PT and PTT within laboratory normal limits\n\nExclusion criteria:\n\n1. Hypersensitivity against active substances and porphyrins.\n2. Known diagnosis of porphyria.\n3. Simultaneous use of other potentially phototoxic substances (eg; tetracyclines, sulphonamides, fluoroquinolones, hypericin extracts).\n4. Uncontrolled concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled cardiac and renal diseases or psychiatric illness.\n5. Subjects with inherited or acquired bleeding and clotting disorders\n6. Women who are breastfeeding\u002F have a positive urine pregnancy test or are planning their family.\n7. Patients who have taken supplements of retinol, beta carotene, vitamin E, Selenium, or other chemo-preventive therapy at least one month prior to the baseline visit.\n8. Patients with histological evidence of no dysplasia, mild dysplasia, invasive carcinoma, and any active malignant disease.\n9. Patients with behavioral and cognitive impairment.\n10. Patients who are concurrently diagnosed and undergoing treatment for other head and neck cancers.\n11. Patients with large lesions, which, in the investigator's opinion, may require reconstructive surgery after excision.\n12. The subjects, in the opinion of the Institutional Principal Investigator, are not an appropriate candidate for study participation due to alcoholism and abstinence.\n13. Patient who was in a clinical trial for 4 weeks before participation in the present trial.",{"count":457,"type":22},65,[89],"The primary goal of this study is to see if photodynamic therapy (PDT) is effective for treatment of lesions in the oral cavity which have high risk of becoming oral cancer. PDT treatment uses a drug, called a photosensitizer, which makes the diseased cells become light-sensitive such that they are destroyed when laser light is delivered to the target lesion. In this study a new handheld device, called SITOS (a \"Screen, Image and Treat Optical System), is used. The ability of this device to simultaneously visualize the inside of the mouth and deliver laser light to the target site will be evaluated. The main questions this study seeks to answer are:\n\n* Can this treatment completely cure oral potentially malignant lesions (OPML) without need for surgery?\n* Do lesions recur after PDT treatment?\n* Is the SITOS device easy to use for the doctor and comfortable for the patient, both as an oral imaging device and as a treatment device?",[28,118,461,462,92],"Oral Leukoplakia","Oral Lichen Planus",[464,465,466,467],"High grade dysplasia (HGD)","Severe\u002FModerate dysplasia","Carcinoma-in-situ (CIS)","Oral potentially malignant lesion (OPML)","2026-03-16",{"date":470,"type":38},"2026-03-19",{"date":472,"type":22},"2026-09",{"date":474,"type":22},"2028-12",{"name":476,"class":45},"University of Massachusetts, Boston",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":46},"100503589","microbiome-in-head-and-neck-squamous-cell-carcinoma-100503589","NCT05837221","Microbiome in Head and Neck Squamous Cell Carcinoma","Role of Human Microbiome in Head and Neck Cancer","Inclusion Criteria:\n\n1. Subjects equal to or above the age of 18.\n2. Patients who are seen and evaluated by a provider within the adult Otolaryngology clinic at the University of Colorado Health.\n3. Patients that present with a diagnosis of OSCC.\n4. An equal number of age-matched patients who are visiting the clinic for reasons other than OSCC diagnoses, as the control group.\n5. Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Subjects under the age of 18 or over the age of 100\n2. Subjects unwilling to particiapte","100 Years",{"count":247,"type":22},"This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.",[29,488,28,489],"Lip Cancer","Pharynx Cancer","2026-02-20",{"date":492,"type":38},"2026-02-24",{"date":494,"type":38},"2025-05-23",{"date":496,"type":22},"2028-10",{"name":498,"class":45},"University of Colorado, Denver",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":245,"sex":18,"minAge":54,"maxAge":160,"enrollmentInfo":506,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":46},"100564427","estimating-jaw-neck-and-shoulder-range-of-motion-using-an-ai-model-100564427","NCT06629038","Estimating Jaw, Neck, and Shoulder Range of Motion Using an AI Model","A Novel Technique for Estimating Maximal Jaw Movement, Neck and Shoulder Joint Range of Motion Using an Artificial Intelligence Model","Inclusion Criteria:\n\n* Healthy adults without a history of head, neck or shoulder injury or surgery, and without HNC-related radiotherapy or chemoradiotherapy\n* Oral cancer patients with trismus, clinical signs of neck or shoulder joint impairment after oral cancer surgery or radiotherapy\n* Age between 20 and 65 years\n\nExclusion Criteria:\n\n* Could not communicate\n* Had any disorder that could influence movement performance",{"count":21,"type":22},"This observational study aims to develop an AI-based system for tracking mandibular and shoulder movements using deep learning techniques. It will compare AI-generated pose estimations with gold standard measurements to assess accuracy, particularly in patients with functional impairments from oral cancer treatment, such as trismus, spinal accessory nerve dysfunction, neck dystonia, and radiation fibrosis.",[28],[510,511,512,513,514,515],"oral cancer","shoulder","range of motion","artificial intelligence","pose estimation","maximal mouth opening","2026-02-09",{"date":518,"type":38},"2026-02-11",{"date":520,"type":38},"2024-12-05",{"date":176,"type":22},{"name":78,"class":45},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":547,"locationsCount":46},"100623892","phase-3-surgery-with-or-without-neoadjuvant-treatment-of-sbrt-plus-chemoimmunotherapy-in-resectable-locally-advanced-oral-and-hpv-unrelated-oropharyngeal-squamous-cell-carcinoma-100623892","NCT07402538","Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","SBRT Followed by Neoadjuvant Chemoimmunotherapy Before Surgery in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma: a Randomized Controlled Phase III Trial","The inclusion criteria for this study are as follows:\n\n* Histologically and\u002For cytologically confirmed treatment-naïve oral squamous cell carcinoma or HPV-negative oropharyngeal squamous cell carcinoma.\n* Clinical stage III -Ⅳa (8th edition of AJCC).\n* Age: 18 to 75 years old.\n* According to the Eastern Cooperative Oncology Group (ECOG) criteria (with a performance status score of 0 or 1).\n* Good organ function.\n* Expected survival time: ≥ 3 months.\n* The patient has signed the informed consent form and is willing and able to comply with the study's scheduled visits, treatment plans, laboratory tests, and other research procedures.\n* Females of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrolment and must agree to use highly effective contraceptive measures during the study period and for at least 60 days after the last dose (including chemotherapeutic drugs and Tislelizumab).\n* If the female partner of a male subject is still of childbearing potential, the male subject must agree to use highly effective contraceptive measures during the study period and for at least 60 days after the last dose.\n\nExclusion Criteria:\n\n* Patients with concurrent other malignant tumors\n* Patients with known or suspected autoimmune diseases, including dementia and epilepsy.\n* Patients with severe mental disorders at the same time\n* Patients with necrotic lesions who are assessed by the investigator as having a risk of massive hemorrhage\n* Patients with severe heart disease or pulmonary dysfunction, and those with cardiac or pulmonary function grade ≤ 3 (grade 3 inclusive)\n* Patients with laboratory test results that do not meet the relevant criteria within 7 days prior to enrollment\n* Received systemic or local glucocorticoid therapy within 4 weeks prior to enrollment\n* Patients with comorbidities requiring long-term treatment with immunosuppressive drugs, or requiring systemic or local administration of corticosteroids at immunosuppressive doses.\n* Patients with active tuberculosis (TB), who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year prior to screening.\n* A history of prior use of anti-Tislelizumab, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulation or checkpoint pathways).\n* Subjects with any active autoimmune diseases or a history of autoimmune diseases (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism); subjects with vitiligo or those whose childhood asthma has been completely relieved and who do not require any intervention in adulthood are eligible for enrollment; those with asthma requiring medical intervention with bronchodilators are not eligible for enrollment.\n* HIV-positive subjects\n* Positive for HBsAg with concurrent positive HBV DNA copy number (quantitative test ≥ 1000 cps\u002Fml); positive for chronic hepatitis C on blood screening (HCV antibody positive)\n* Received any anti-infective vaccines (such as influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment\n* Pregnant women with positive pregnancy test results among females of childbearing potential and lactating women.","75 Years",{"count":532,"type":22},184,[534],"PHASE3","The objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free survival rate and overall survival rate in patients diagnosed with locally advanced oral or HPV-unrelated oropharyngeal cancer.",[28,537],"Oropharyngeal Cancer",[539,540,541],"SBRT","neoadjuvant therapy","locally advanced oral\u002Foropharyngeal cancer","2026-02-04",{"date":518,"type":38},{"date":492,"type":22},{"date":546,"type":22},"2030-12-31",{"name":548,"class":45},"Sun Yat-sen University",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":55,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":562,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":46},"100623823","effect-of-dezocine-versus-nalbuphine-combined-with-sufentanil-on-postoperative-analgesia-complications-and-free-flap-survival-in-patients-undergoing-oral-cancer-radical-surgery-a-randomized-controlled-clinical-trial-100623823","NCT07401641","Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n1. Diagnosed with oral malignant tumor.\n2. Scheduled for oral cancer radical surgery with free flap reconstruction at Sun Yat-sen Memorial Hospital.\n3. Age between 18 and 70 years.\n4. Sign informed consent.\n\nExclusion Criteria:\n\n1. Use of analgesic medications within two weeks prior to surgery.\n2. History of diabetes, arteriosclerosis, or peripheral vascular disease.\n3. Use of hormones, chemotherapy, or immunosuppressants.\n4. Severe cardiac, pulmonary, hematological, hepatic, or renal diseases.\n5. Known allergy to the study drugs.",{"count":247,"type":22},[25],"Background: Oral cancer radical surgery often requires free flap reconstruction. Postoperative pain is severe, and traditional opioids like sufentanil have side effects and may adversely affect tumor biology. Dezocine and nalbuphine are opioid agonist-antagonists with potentially better safety profiles. Their comparative effects on analgesia, complications, and flap survival in oral cancer surgery are unknown.\n\nObjective: To compare the efficacy of dezocine versus nalbuphine, both combined with sufentanil, for postoperative analgesia, and to evaluate their impact on postoperative complications and free flap survival\u002Ffunction in patients undergoing oral cancer radical surgery with flap reconstruction.\n\nMethods: This is a prospective, randomized, double-blind, controlled trial. Sixty eligible patients (aged 18-70, ASA I-III) will be randomly assigned (1:1) to receive postoperative patient-controlled intravenous analgesia (PCIA) with either Sufentanil + Dezocine or Sufentanil + Nalbuphine. The primary outcome is pain intensity assessed by the Visual Analogue Scale (VAS) at 2, 24, and 48 hours postoperatively. Secondary outcomes include flap survival status, sensory function recovery, incidence of adverse events (e.g., nausea, vomiting), and hospitalization duration.\n\nPotential Impact: This study may identify a superior postoperative analgesic regimen that provides effective pain relief while potentially improving flap outcomes and minimizing side effects for oral cancer patients.",[28,559,560,561],"Postoperative Pain Management","Free Tissue Flaps","Mouth Neoplasms",[563,564,565,566,567,568,569],"Dezocine","Nalbuphine","Oral Cancer Surgery","Free Flap Reconstruction","Postoperative Analgesia","Randomized Controlled Trial","Flap Survival","2026-02-03",{"date":572,"type":38},"2026-02-10",{"date":574,"type":38},"2025-06-01",{"date":123,"type":22},{"name":577,"class":45},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":592,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":603,"locationsCount":4},"100616510","effectiveness-of-hydrogen-water-intervention-on-acute-oral-inflammation-oral-microbiota-and-pain-following-free-flap-reconstruction-in-patients-with-oral-cancer-100616510","NCT07306546","Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer","Inclusion Criteria:\n\n* Diagnosed with oral cancer and receiving microsurgical free flap reconstruction.\n* Age 18 years or older.\n* Conscious and able to follow study instructions.\n* Able to communicate without difficulty in Mandarin, Taiwanese, or through written communication.\n\nExclusion Criteria:\n\n* Abnormal salivary gland function or severe xerostomia.\n* Recent use of antibacterial mouthwash or antibiotic therapy that may affect oral microbiota.\n* Presence of severe bacterial or viral oral infections, or significant periodontal disease.",{"count":585,"type":22},36,[25],"This study employs a Randomized Controlled Trial (RCT) design. Patients diagnosed with oral cancer by the attending physician and who meet the inclusion criteria will be admitted to the study after receiving a full explanation of the study objectives, intervention methods, potential risks, and participant rights from the research team upon their stable transfer to the plastic surgery ward post-operation. Written consent will be obtained from the patient and\u002For their legally authorized representative after adequate informed consent has been provided, before they are enrolled in the study.",[589,590,591,566,28],"Oral Squamous Cell Carcinoma (OSCC)","Postoperative Pain","Postoperative Oral Mucositis",[593,63,594,595,596],"Hydrogen water","Free flap reconstruction","Pain assessment","Salivary Biomarkers","2025-12-25",{"date":599,"type":38},"2025-12-29",{"date":601,"type":22},"2026-01",{"date":266,"type":22},{"name":604,"class":45},"Kaohsiung Medical University Chung-Ho Memorial Hospital",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":46},"100616087","app-assisted-swallowing-program-after-oral-cancer-surgery-100616087","NCT07301047","App-Assisted Swallowing Program After Oral Cancer Surgery","AASP","Inclusion Criteria:\n\n* Willing to sign a written informed consent form\n* Diagnosed with oral cancer\n* Hospitalized for first-time oral cancer tumor resection and flap reconstruction surgery\n* Aged 18 years or older\n* Conscious and mentally clear\n* Able to communicate in Mandarin or Taiwanese\n\nExclusion Criteria:\n\n* Diagnosed by a physician with poor postoperative wound healing that prevents participation in oral rehabilitation exercises\n* Unable to perform oral rehabilitation exercises within one week after surgery, as determined by a physician\n\nWithdrawal Criteria:\n\n-Participants who withdraw consent at any time during the study will be excluded from further participation",{"count":613,"type":22},72,[25],"This study aims to examine the effects of a swallowing care program combined with an exercise mobile application (App) on swallowing function, anxiety, and quality of life in patients with oral cancer after flap reconstruction surgery. The goal is to determine whether integrating App-based swallowing exercises into postoperative care can improve rehabilitation outcomes compared with conventional care alone.\n\nA purposive sampling method will be used to recruit 72 participants from the surgical wards of a medical center in northern Taiwan. Eligible patients scheduled for oral cancer tumor resection and flap reconstruction will be identified through consultation with plastic surgeons. After screening and informed consent, participants will be assigned to a control group or an experimental group, with approximately 36 patients in each group.\n\nThe control group will receive routine ward education and standard postoperative nursing care, while the experimental group will receive the same care plus an additional intervention using a swallowing exercise App. The intervention will begin on postoperative day 7, guided by the researcher. Follow-up assessments will be conducted during outpatient visits at postoperative week 4 and week 12. To minimize potential interference between participants, data collection will be performed sequentially-first for the control group, followed by the experimental group.\n\nData will be collected through self-administered questionnaires or researcher-assisted interviews, including a demographic survey, the Postoperative Oral Dysfunction-10 (POD-10), the Functional Oral Intake Scale (FOIS), a Visual Analog Scale for Anxiety, and the EORTC QLQ-H\\&N35 questionnaire for quality of life. Each assessment will take approximately 20-30 minutes. Participants may withdraw from the study at any time without penalty.\n\nDescriptive statistics will be used to summarize participant characteristics. The chi-square test and independent t-test will be used to examine group homogeneity. Paired t-tests will be applied to evaluate within-group changes in swallowing function, anxiety, and quality of life before and after the intervention. The results of this study are expected to provide empirical evidence on the effectiveness of App-assisted swallowing rehabilitation for patients with oral cancer following reconstructive surgery, supporting the development of innovative, technology-based postoperative care models.",[28,617,618],"Reconstructive Surgery","Postoperative",[28,618,617],"2025-12-23",{"date":622,"type":38},"2025-12-24",{"date":624,"type":22},"2026-01-01",{"date":176,"type":22},{"name":627,"class":45},"Chang Gung Memorial Hospital",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":245,"sex":18,"minAge":635,"maxAge":636,"enrollmentInfo":637,"targetDuration":4,"studyType":23,"phases":638,"briefSummary":639,"conditions":640,"keywords":641,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":46},"100615718","circulating-tumor-cell-counts-in-postoperative-ene-positive-oral-cavity-cancer-patients-after-adjuvant-ccrt-100615718","NCT07296250","Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT","A Randomized, Prospective Phase II Clinical Trial - Extended Chemotherapy or Not Based on Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Completing Adjuvant Concurrent Chemoradiotherapy","Inclusion Criteria:\n\nParticipants with Cancer:\n\n1. Aged between 18 and 90 years.\n2. Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).\n3. Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.\n4. Willing to continue follow-up visits at the hospital after completion of treatment.\n\nExclusion Criteria:\n\n1. Presence of psychiatric disorders.\n2. Deemed unsuitable for participation by the attending physician.\n3. Unwilling to participate in the study.","18 Months","90 Years",{"count":406,"type":22},[25],"The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.",[29,28],[510,642,643,644,645],"ENE","Circulating tumor cells","Adjuvant concurrent Chemoradiation, adjuvant CCRT","Circulating tumor microemboli (CTM)","2025-12-08",{"date":648,"type":38},"2025-12-22",{"date":650,"type":38},"2025-08-01",{"date":652,"type":22},"2028-07-31",{"name":627,"class":45},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":4,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":661,"targetDuration":4,"studyType":23,"phases":662,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":46},"100611214","ai-based-physiotherapy-3--and-9-month-follow-up-in-oral-cancer-patients-100611214","NCT07237672","AI Based Physiotherapy 3- and 9-Month Follow-Up in Oral Cancer Patients","Effects of AI Based Physiotherapy on Mandibular Mobility Shoulder Function Whole Body Physical Function Quality of Life and Return to Work in Oral Cancer Patients: 3- and 9-Month Postintervention Follow-Up","Inclusion Criteria:\n\n* Participants who completed the intervention phase of the previous trial (202411044RINC)\n* Age 20-65 years\n* Able to attend follow-up assessments at 3 and 9 months\n\nExclusion Criteria:\n\n* Withdrawal from the original trial\n* Cancer recurrence or new cancer-related treatment interfering with functional assessment\n* Unable to communicate or comply with follow-up visits",{"count":457,"type":22},[25],"This follow-up clinical study aims to evaluate the sustained effects of two rehabilitation programs (AI-based physiotherapy vs. conventional physiotherapy) for oral cancer patients. Participants who completed the original intervention trial (ClinicalTrials.gov ID: 202411044RINC) will be assessed at 3 and 9 months post-intervention. Outcomes include mandibular mobility, shoulder joint range of motion, functional performance, quality of life, pain, and return-to-work status.",[28],[64,63,65,411,306,66],{"date":667,"type":38},"2025-12-16",{"date":669,"type":38},"2025-12-06",{"date":671,"type":22},"2027-12",{"name":78,"class":45}]